RS52911B2 - Lečenje simptoma parkinsonove bolesti sa alkilamin histaminom bez imidazola - x3 - receptora liganda - Google Patents

Lečenje simptoma parkinsonove bolesti sa alkilamin histaminom bez imidazola - x3 - receptora liganda

Info

Publication number
RS52911B2
RS52911B2 RSP20130359A RS52911B2 RS 52911 B2 RS52911 B2 RS 52911B2 RS P20130359 A RSP20130359 A RS P20130359A RS 52911 B2 RS52911 B2 RS 52911B2
Authority
RS
Serbia
Prior art keywords
disease
parkinson
compound
treatment
daytime sleepiness
Prior art date
Application number
Other languages
English (en)
Serbian (sr)
Inventor
Jean-Charles Schwartz
Jeanne Marie Lecomte
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35169680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52911(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of RS52911B publication Critical patent/RS52911B/sr
Publication of RS52911B2 publication Critical patent/RS52911B2/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20130359 2005-04-01 2006-03-30 Lečenje simptoma parkinsonove bolesti sa alkilamin histaminom bez imidazola - x3 - receptora liganda RS52911B2 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05290727A EP1707203A1 (en) 2005-04-01 2005-04-01 Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
US66861805P 2005-04-06 2005-04-06
PCT/IB2006/000739 WO2006103546A2 (en) 2005-04-01 2006-03-30 Treatment of parkinson's disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3-receptor ligands
EP06744466.1A EP1863487B2 (en) 2005-04-01 2006-03-30 Treatment of symptoms of parkinson's disease with non-imidazole alkylamines histamine h3-receptor ligands

Publications (2)

Publication Number Publication Date
RS52911B RS52911B (sr) 2014-02-28
RS52911B2 true RS52911B2 (sr) 2019-11-29

Family

ID=35169680

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20130359 RS52911B2 (sr) 2005-04-01 2006-03-30 Lečenje simptoma parkinsonove bolesti sa alkilamin histaminom bez imidazola - x3 - receptora liganda

Country Status (27)

Country Link
US (1) US8486947B2 (OSRAM)
EP (2) EP1707203A1 (OSRAM)
JP (3) JP5546761B2 (OSRAM)
KR (1) KR101308527B1 (OSRAM)
CN (1) CN101171009B (OSRAM)
AU (1) AU2006228413C1 (OSRAM)
BR (1) BRPI0612216B1 (OSRAM)
CA (1) CA2603656C (OSRAM)
CY (1) CY1114636T1 (OSRAM)
DK (1) DK1863487T4 (OSRAM)
EA (1) EA016007B1 (OSRAM)
ES (1) ES2426008T5 (OSRAM)
HR (1) HRP20130748T4 (OSRAM)
MA (1) MA29353B1 (OSRAM)
ME (1) ME01713B (OSRAM)
MX (1) MX2007012162A (OSRAM)
NO (1) NO343603B1 (OSRAM)
NZ (1) NZ561940A (OSRAM)
PL (1) PL1863487T5 (OSRAM)
PT (1) PT1863487E (OSRAM)
RS (1) RS52911B2 (OSRAM)
SG (1) SG147415A1 (OSRAM)
SI (1) SI1863487T2 (OSRAM)
TN (1) TNSN07365A1 (OSRAM)
UA (1) UA94902C2 (OSRAM)
WO (1) WO2006103546A2 (OSRAM)
ZA (1) ZA200708086B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090024811A (ko) 2006-06-23 2009-03-09 아보트 러보러터리즈 히스타민 ｈ3 수용체 조절제로서의 사이클로프로필 아민 유도체
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
CA2658821C (en) 2006-07-25 2014-10-21 Cephalon, Inc. Pyridizinone derivatives and uses thereof to treat diseases, disorders and/or conditions that may be mediated or modulated by inhibition of h3 receptors
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
MX2010008375A (es) 2008-01-30 2011-03-04 Cephalon Inc Star Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
FR2932479A1 (fr) 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US9181275B2 (en) 2011-08-11 2015-11-10 Abbvie Inc. Mercaptoamidine derivatives and methods of use
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
BR112015007641A8 (pt) * 2012-10-05 2018-04-03 Vtv Therapeutics Llc Tratamento da doença de alzheimer branda e moderada
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US20200282215A1 (en) 2019-03-06 2020-09-10 Medtronic Xomed, LLC Evaluating stimulation eficacy for treating sleep apnea and lingual muscle tone sensing system for improved osa therapy
EP4248969A1 (en) 2022-03-23 2023-09-27 Bioprojet Use of pitolisant for treating severe fatigue
AU2024246127A1 (en) 2023-03-31 2025-10-09 Bioprojet Pharma Polymorph form of pitolisant hydrochloride
TW202535387A (zh) * 2023-10-16 2025-09-16 法商拜爾普羅傑特醫藥有限公司 必托里賽（ｐｉｔｏｌｉｓａｎｔ）之新穎調配物及使用方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815945A (ja) * 1981-07-21 1983-01-29 Teikoku Hormone Mfg Co Ltd 新規なフエノキシアルキルアミン誘導体
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
JPH06505265A (ja) 1991-02-27 1994-06-16 シード・キャピタル・インベストメント・（エス・シー・アイ）・ベスローテン・フェンノートシャップ ヒスタミンｈ↓３受容体に対する作動的または拮抗的活性を有するイミダゾール誘導体
NZ246441A (en) 1991-12-18 1996-02-27 Schering Corp Imidazol or imidazolalkyl substituted with a 4 or 5 membered nitrogen containing heterocycle, preparation and pharmaceutical compositions thereof
KR0142801B1 (en) 1991-12-18 1998-07-15 Schering Corp Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring t
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5380858A (en) 1992-04-01 1995-01-10 The University Of Toledo Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
US5639775A (en) 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
KR960701858A (ko) 1993-01-25 1996-03-28 가와노 다케히코 이미다졸계 화합물(Imidazole-series compound)
JP3522790B2 (ja) 1993-06-08 2004-04-26 花王株式会社 Ｈ３−レセプター刺激薬
AU7823894A (en) 1993-08-27 1995-03-21 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
JPH09505298A (ja) 1993-11-15 1997-05-27 シェーリング コーポレイション Ｈ▲下３▼‐レセプターアンタゴニストとしてのフェニル‐アルキルイミダゾール
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
AU721325B2 (en) 1995-05-30 2000-06-29 Gliatech Inc. 1H-4(5)-substituted imidazole derivatives
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
DE69623784T2 (de) 1995-06-07 2003-05-15 Gliatech, Inc. 1h-4(5)-substituierte imidazolderivate.
AU709611B2 (en) 1996-02-09 1999-09-02 James Black Foundation Limited Histamine h3 receptor ligands
JP3925579B2 (ja) * 1998-02-03 2007-06-06 日本精工株式会社 潤滑剤供給体、並びに前記潤滑剤供給体を備える転がり軸受、リニアガイド装置及びボールねじ装置
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
CN1155558C (zh) * 1999-06-11 2004-06-30 富山化学工业株式会社 N-烷氧基烷基-n,n-二烷基胺衍生物或其盐以及含有它们的用于治疗神经变性疾病的治疗剂
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
AU2001284733B2 (en) * 2000-08-08 2006-11-02 Ortho-Mcneil Pharmaceutical, Inc. Non-imidazole aryloxyalkylamines as H3 receptor ligands
US20020042400A1 (en) * 2000-08-17 2002-04-11 Yajing Rong Novel alicyclic imidazoles as H3 agents
WO2002015905A1 (en) * 2000-08-21 2002-02-28 Gliatech, Inc. The use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
JP4653935B2 (ja) * 2001-03-29 2011-03-16 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ヒスタミンｈ３受容体のリガンドとして用いるに有用なイミダゾリル誘導体
EP1451225A1 (en) * 2001-11-15 2004-09-01 Ortho-McNeil Pharmaceutical, Inc. Agonists of recombinant human histamine h3 receptor
DE60209794T2 (de) * 2001-12-10 2006-11-09 Ortho-Mcneil Pharmaceutical, Inc. Phenylalkyne
JP2006505590A (ja) * 2002-10-23 2006-02-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ３受容体調節物質としてのフェニルピペリジンおよびフェニルピロリジン
EP1642898B1 (en) * 2003-06-27 2013-03-27 Msd K.K. Heteroaryloxy nitrogenous saturated heterocyclic derivative
FR2856596B1 (fr) * 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
SE0302116D0 (sv) * 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
ATE547404T1 (de) * 2003-09-22 2012-03-15 Msd Kk Piperidinderivate

Also Published As

Publication number Publication date
NZ561940A (en) 2010-06-25
HRP20130748T4 (hr) 2019-11-15
BRPI0612216A2 (pt) 2010-10-26
BRPI0612216B1 (pt) 2022-04-19
MX2007012162A (es) 2007-11-22
DK1863487T3 (da) 2013-08-12
JP5546761B2 (ja) 2014-07-09
JP5955872B2 (ja) 2016-07-20
ZA200708086B (en) 2008-10-29
EP1863487B2 (en) 2019-07-17
KR20080002904A (ko) 2008-01-04
PT1863487E (pt) 2013-08-29
SI1863487T2 (sl) 2019-11-29
ES2426008T5 (es) 2020-03-20
AU2006228413B2 (en) 2011-09-15
SI1863487T1 (sl) 2013-09-30
MA29353B1 (fr) 2008-03-03
CA2603656C (en) 2015-06-16
CN101171009B (zh) 2012-11-07
JP2014062126A (ja) 2014-04-10
US20090318433A1 (en) 2009-12-24
KR101308527B1 (ko) 2013-09-17
PL1863487T5 (pl) 2021-08-09
PL1863487T3 (pl) 2014-10-31
AU2006228413C1 (en) 2012-02-02
SG147415A1 (en) 2008-11-28
CY1114636T1 (el) 2016-10-05
DK1863487T4 (da) 2019-10-14
JP2008534572A (ja) 2008-08-28
ME01713B (me) 2014-09-20
ES2426008T3 (es) 2013-10-18
JP2016106142A (ja) 2016-06-16
US8486947B2 (en) 2013-07-16
EA200702135A1 (ru) 2008-04-28
EA016007B1 (ru) 2012-01-30
HRP20130748T1 (en) 2013-10-11
WO2006103546A3 (en) 2007-03-01
NO343603B1 (no) 2019-04-08
UA94902C2 (ru) 2011-06-25
CA2603656A1 (en) 2006-10-05
RS52911B (sr) 2014-02-28
CN101171009A (zh) 2008-04-30
EP1863487B1 (en) 2013-05-29
NO20075086L (no) 2007-12-27
TNSN07365A1 (fr) 2008-12-31
WO2006103546A2 (en) 2006-10-05
EP1863487A2 (en) 2007-12-12
EP1707203A1 (en) 2006-10-04
AU2006228413A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
RS52911B2 (sr) Lečenje simptoma parkinsonove bolesti sa alkilamin histaminom bez imidazola - x3 - receptora liganda
AU2009257572C1 (en) Low dose topiramate/phentermine composition and methods of use thereof
JP2000507544A (ja) 痛みの治療方法
TW200808696A (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
CA2692042A1 (en) Compositions and methods for treating obesity and related disorders
TWI453013B (zh) N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
EP1030667B1 (en) Use of mirtazapine for the manufacture of a medicament for treating sleep apneas
CN110267657B (zh) 氨基甲酸酯化合物用于预防、缓解或治疗震颤或震颤综合征的用途
EP0818198A1 (en) Potentiation of drug response by increasing serotonin availability
HK40015061A (en) Use of carbamate compounds for preventing, alleviating, or treating tremors or tremor syndrome
HK40015061B (en) Use of carbamate compounds for preventing, alleviating, or treating tremors or tremor syndrome
EA047115B1 (ru) Способы и композиции для лечения апноэ сна
MXPA00004609A (en) Use of mirtazapine for treating sleep apneas
AU2014202143A1 (en) Low Dose Topiramate / Phentermine Composition and Methods of Use Thereof
HK1029932B (en) Use of mirtazapine for the manufacture of a medicament for treating sleep apneas